Despite lots of talk about strategy and synergy, the deal will be dilutive to earnings, and investors weren't inclined to be supportive. Bear Stearns and John G. Kinnard also lowered their ratings on stock. Until a few days ago, that is. IDEC's CEO said that estimates for sales of its lead cancer drug, Rituxan, were too high. Speaking of comebacks, take a look at Compaq .
Net stocks are way back, at least for now.
Next week's slated IPOs are ALL 'Net related. What a shock. Poor confused Chase . Chase professes utter confusion over the events of the lst few days. It's an analyst story, not a company story.